AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq

Summary:

  • AbbVie Inc.’s Q4 revenue beat expectations, a positive sign considering the expiration of Humira exclusivity in 2023.
  • Skyrizi and Rinvoq contributed $3.7 billion to Q4 revenue, showing strong growth that prompted the company to guide up its 2027 sales projections by $6 billion.
  • AbbVie’s stock is technically strong and has room for further upside before becoming overbought.

Abbvie Ahead Of Earnings Figures

Bloomberg/Bloomberg via Getty Images

AbbVie Inc. (NYSE:ABBV) recently reported its Q4 results as Seeking Alpha has covered here. The stock went up less than 1% after the earnings but is up nearly 9% YTD. 2023 was expected to be a


Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *